Compare BIO & CTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | CTRE |
|---|---|---|
| Founded | 1952 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 9.9B |
| IPO Year | 1994 | 2013 |
| Metric | BIO | CTRE |
|---|---|---|
| Price | $364.61 | $36.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $328.33 | $44.62 |
| AVG Volume (30 Days) | 256.4K | ★ 2.1M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | ★ 142.61 | 96.25 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $2,583,200,000.00 | $476,393,000.00 |
| Revenue This Year | N/A | $36.44 |
| Revenue Next Year | $2.13 | $22.85 |
| P/E Ratio | ★ N/A | $48.74 |
| Revenue Growth | 0.65 | ★ 60.79 |
| 52 Week Low | $236.73 | $32.79 |
| 52 Week High | $396.23 | $43.62 |
| Indicator | BIO | CTRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 41.64 |
| Support Level | $358.85 | $35.85 |
| Resistance Level | $392.81 | $40.12 |
| Average True Range (ATR) | 12.52 | 0.57 |
| MACD | -2.22 | 0.02 |
| Stochastic Oscillator | 30.27 | 52.69 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
CareTrust REIT Inc is a self-administered, publicly traded REIT engaged in the ownership, acquisition, financing, development, and leasing of skilled nursing, seniors housing, and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators under triple-net lease arrangements, in which the tenant is solely responsible for property-related costs. The company operates in Domestic and Foreign markets, with the majority of revenue coming from Domestic operations.